Dolby Laboratories, Inc.·4

May 6, 5:05 PM ET

Couling John D 4

4 · Dolby Laboratories, Inc. · Filed May 6, 2026

Research Summary

AI-generated summary of this filing

Updated

Dolby (DLB) SVP John Couling Sells Shares, Exercises Options

What Happened

  • John D. Couling, Senior Vice President, Entertainment at Dolby Laboratories (DLB), executed both stock sales and an options exercise. The filing shows sales of 12,354 shares across May 4–5, 2026, generating roughly $715,294 in proceeds. On May 5 he also exercised options to acquire 7,666 shares at $45.50 per share for about $348,803. A separate derivative line at $0 in the filing is a reporting detail related to the exercise/conversion.
  • Overall, Couling sold more shares than he acquired: total sales (12,354) minus shares acquired by exercise (7,666) equals a net reduction of 4,688 shares. The exercised options were part of a grant (total grant = 46,000 shares) and the option exercised was fully vested as of the transaction date (footnote F4).

Key Details

  • Transaction dates: May 4–5, 2026. Filing date: May 6, 2026 (appears timely).
  • Sales: 4,688 @ $58.47 (5/4) = $274,084; 6,928 @ $57.47 (5/5) = $398,158; 738 @ $58.34 (5/5) = $43,052. Total sales ≈ $715,294. Footnotes F2/F3 note the sales were executed in multiple transactions under a 10b5-1 plan adopted Feb 3, 2026; weighted-average prices and price ranges are provided in the filing.
  • Exercise: 7,666 shares acquired via option exercise @ $45.50 = ~$348,803. Footnote F4: the option exercised was fully vested; the grant covered 46,000 shares.
  • Shares held after transactions: filing notes holdings include 55,114 shares underlying restricted stock units (RSUs) that remain subject to forfeiture until vesting (footnote F1).
  • Filing timeliness: Report filed two days after the first reported transaction; no late-filing designation noted.

Context

  • The sales were made under a 10b5-1 trading plan, which is a pre-arranged plan that allows insiders to sell shares according to a preset schedule; such sales are often routine and not an immediate indicator of changed sentiment.
  • The filing shows an option exercise (he paid to acquire shares). When exercises and sales occur on the same dates, filings can reflect both the acquisition and separate open-market sales; the document here reports both but does not explicitly tie specific exercised shares to particular sales.
  • For retail investors: purchases/exercises can signal confidence but are often part of compensation or tax/cash-management decisions; sales executed under a 10b5-1 plan are typically pre-planned and routine.

Insider Transaction Report

Form 4
Period: 2026-05-04
Couling John D
SVP, Entertainment
Transactions
  • Sale

    Class A Common Stock

    [F1]
    2026-05-04$58.47/sh4,688$274,084118,353 total
  • Exercise/Conversion

    Class A Common Stock

    [F1]
    2026-05-05$45.50/sh+7,666$348,803126,019 total
  • Sale

    Class A Common Stock

    [F2][F1]
    2026-05-05$57.47/sh6,928$398,158119,091 total
  • Sale

    Class A Common Stock

    [F3][F1]
    2026-05-05$58.34/sh738$43,052118,353 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    [F4]
    2026-05-057,66638,334 total
    Exercise: $45.50Exp: 2026-12-15Class A Common Stock (7,666 underlying)
Footnotes (4)
  • [F1]Shares held following the reported transactions include 55,114 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.
  • [F2]The shares were sold in multiple transactions at prices ranging from $57.16 to $58.05 , inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 3, 2026.
  • [F3]The shares were sold in multiple transactions at prices ranging from $58.195 to $58.36, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 3, 2026.
  • [F4]This option was granted for a total of 46,000 shares of Class A Common Stock. The option exercised in this transation was fully vested and exercisable as of the transaction date.
Signature
/s/ Daniel Rodriguez as Attorney-in-Fact for John Couling|2026-05-06

Documents

1 file
  • 4
    ownership.xmlPrimary

    4